The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

Conditions: Prostate Cancer Interventions: Drug: Relugolix 120 MG [Orgovyx]; Radiation: SBRT standard of care radiotherapy treatment Sponsors: Yale University; Pfizer Not yet recruiting

https://clinicaltrials.gov/study/NCT06111781

Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials